Valuation: Cipla Limited

Market Cap 1,073B 11.33B 10.11B 9.4B 8.55B 16.08B 16.37B 113B 44.16B 560B 42.51B 41.61B 1,791B P/E 2027 *
25.9x
P/E 2028 * 20.8x
Enterprise Value 967B 10.21B 9.11B 8.47B 7.7B 14.49B 14.75B 102B 39.8B 504B 38.3B 37.49B 1,614B EV / Sales 2027 *
3.13x
EV / Sales 2028 * 2.71x
Free-Float
68.87%
Yield 2027 *
0.98%
Yield 2028 * 1.11%
1 day-1.43%
1 week+0.73%
Current month-2.13%
1 month-3.50%
3 months-8.00%
6 months+6.15%
Current year-17.86%
1 week 13.5
Extreme 13.5
14
1 month 13.5
Extreme 13.5
14.6
Current year 12.8
Extreme 12.8
17
1 year 12.8
Extreme 12.8
18.9
3 years 12.8
Extreme 12.8
20
5 years 10.4
Extreme 10.4
20
10 years 4.94
Extreme 4.94
20
Manager TitleAgeSince
Chief Executive Officer - 31/03/2026
Director of Finance/CFO - 23/07/2026
President - 17/05/2026
Director TitleAgeSince
Chairman 90 21/07/1972
Director/Board Member 72 24/07/2014
Director/Board Member 71 29/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.43%+0.73% - - 11.16B
+4.64%+7.96%+52.77%+104.78% 1,077B
+0.17%-0.73%+33.19%+61.63% 612B
+1.79%+5.16%+26.64%+94.58% 501B
+0.52%+3.99%+76.03%+42.17% 364B
+2.37%+7.66%+33.65%+50.58% 353B
+2.64%+6.95%+21.01%+44.38% 278B
+3.24%+6.78%+0.43%+15.73% 251B
+3.47%+8.11%+48.15%+53.54% 230B
+3.78%+8.15%+34.48%+100.88% 190B
Average +2.08%+1.97%+36.26%+63.14% 428.5B
Weighted average by Cap. +2.58%+1.58%+39.84%+72.34%

Financials

2027 *2028 *
Net sales 309B 3.27B 2.91B 2.71B 2.46B 4.64B 4.72B 32.54B 12.73B 161B 12.25B 12B 516B 347B 3.66B 3.27B 3.04B 2.76B 5.2B 5.29B 36.49B 14.28B 181B 13.74B 13.45B 579B
Net income 41.18B 435M 388M 361M 328M 617M 628M 4.33B 1.7B 21.49B 1.63B 1.6B 68.76B 51.59B 545M 486M 452M 411M 773M 787M 5.43B 2.12B 26.92B 2.04B 2B 86.13B
Net Debt -106B -1.12B -1B -929M -845M -1.59B -1.62B -11.16B -4.37B -55.36B -4.2B -4.11B -177B -131B -1.39B -1.24B -1.15B -1.05B -1.97B -2.01B -13.83B -5.41B -68.58B -5.21B -5.1B -219B
Projected Income Statement - Annual - Cipla Limited
Logo Cipla Limited
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Employees
31,369
Date Price Change
14/10/26 US$13.80 -1.43%
13/10/26 US$14.00 +2.19%
12/10/26 US$13.70 +1.48%
09/10/26 US$13.50 0.00%
08/10/26 US$13.50 -1.46%
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Cipla Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1,328.00INR
Average target price
1,512.19INR
Spread / Average Target
+13.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cipla Limited